[Edaily Reporter Kwon Oh Seok ] #Curiosis Inc., a company specializing in lab automation, is conducting a stock split to enhance shareholder value and broaden its investor base.

Curiosis Inc. announced that it held a board of directors meeting on the morning of the 29th and resolved to carry out a stock split, allocating one new share for every existing share of common stock, totaling 7,629,882 shares. As a result, the total number of issued shares will double from 7,629,882 to 15,259,764. The record date for the new shares is July 16, and the scheduled listing date is August 10. The company plans to fund the issuance using its capital surplus (share premium).
A company official stated, “This stock split is part of our commitment to responsible management, aimed at improving investor accessibility and enhancing shareholder value by increasing the number of shares in circulation in the capital market,” adding, “It reflects the management’s determination to share the fruits of our growth with shareholders who have trusted and supported the company.”
Since listing on the KOSDAQ market late last year, Curiosis Inc. has been aggressively pursuing ODM (Original Design Manufacturing) collaborations with global biotech companies and expanding its supply chain for proprietary brands such as “Celloger®.” Following the recent expansion of its supply contract with global biotech firm Revvity, the company is preparing partnerships with additional global biotech firms, thereby actively growing its ODM business—a core growth strategy.
CEO Yoon Ho-young stated, “Even amid an uncertain market environment, as a publicly listed company, we will prioritize shareholder-friendly policies and solidify investor trust through transparent market communication.” He added, “We will continuously enhance corporate value by expanding global ODM orders, strengthening our core business competitiveness through the full-scale operation of our expanded Yongin plant, expanding our organoid lineup, and expanding into new businesses such as the development of new autonomous laboratory products.”